| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biochemistry and Biophysics |
Department of Medicine and Committee on Cancer Biology, University of Chicago, Chicago Illinois 60637 [C. M. R., D. J. V.]; Division of Hematology/Oncology, Vincent T. Lombardi Cancer Center, Washington, D.C. 20007 [Z. Y., L. M. S., K. N., K. J. C.]; and Program of Molecular Therapeutics and Drug Discovery, Departments of Medicine and Pharmacology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213 [M. J. E., E. G. Z.].
Cisplatin is a potent cytotoxic agent that functions as a bivalent electrophile, forming both interstrand and intrastrand DNA cross-links. Cisplatin-mediated DNA damage results in cell cycle arrest and initiation of apoptotic cell death. Increased cellular glutathione concentrations have been closely correlated with cisplatin resistance but do not reduce the extent of cisplatin-DNA adduct formation. One hypothesis to explain the ability of glutathione to inhibit cisplatin cytotoxicity is that glutathione, through its antioxidant function, plays a role in apoptotic regulatory pathways. We tested this hypothesis using MCF-7 breast cancer cells transfected with the apoptotic inhibitor Bcl-2. Bcl-2 overexpression in MCF-7 cells was associated with a nearly 3-fold increase in cellular glutathione levels and with increased resistance to cell death after cisplatin exposure. Treatment of MCF-7 lines with buthionine sulfoximine, an inhibitor of glutathione synthesis, normalized glutathione levels in Bcl-2 and control transfectants and completely abrogated Bcl-2-mediated cisplatin resistance without affecting Bcl-2 expression. Bcl-2 overexpression and up-regulation of glutathione were not associated with a change in either cisplatin-DNA adduct formation or repair over time. These results suggest that Bcl-2-mediated cisplatin resistance in MCF-7 cells is dependent on up-regulation of glutathione production, which contributes to cell survival by mechanisms independent of cisplatin inactivation or inhibition of DNA adduct formation. A similar dependence on glutathione for Bcl-2-mediated inhibition of cisplatin toxicity was confirmed in a second cell line, the lymphocytic precursor FL5.12. Taken together, these data suggest that apoptotic signaling after genotoxic exposure can be inhibited by the antioxidant activity of glutathione. Inhibition of glutathione synthesis or modulation of glutathione stores in tumors that overexpress Bcl-2 may comprise a novel anticancer strategy.
This article has been cited by other articles:
![]() |
E. W. LaPensee, S. J. Schwemberger, C. R. LaPensee, E. M. Bahassi, S. E. Afton, and N. Ben-Jonathan Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase Carcinogenesis, August 1, 2009; 30(8): 1298 - 1304. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Brozovic, D. Majhen, V. Roje, N. Mikac, S. Jakopec, G. Fritz, M. Osmak, and A. Ambriovic-Ristov {alpha}v{beta}3 Integrin-Mediated Drug Resistance in Human Laryngeal Carcinoma Cells Is Caused by Glutathione-Dependent Elimination of Drug-Induced Reactive Oxidative Species Mol. Pharmacol., July 1, 2008; 74(1): 298 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, P. Chanvorachote, D. Toledo, C. Stehlik, R. R. Mercer, V. Castranova, and Y. Rojanasakul Peroxide Is a Key Mediator of Bcl-2 Down-Regulation and Apoptosis Induction by Cisplatin in Human Lung Cancer Cells Mol. Pharmacol., January 1, 2008; 73(1): 119 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Santangelo, P. Matarrese, R. Masella, M. C. Di Carlo, A. Di Lillo, B. Scazzocchio, E. Vecci, W. Malorni, R. Perfetti, and E. Anastasi Hepatocyte growth factor protects rat RINm5F cell line against free fatty acid-induced apoptosis by counteracting oxidative stress J. Mol. Endocrinol., January 1, 2007; 38(1): 147 - 158. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Yang, L. M. Schumaker, M. J. Egorin, E. G. Zuhowski, Z. Guo, and K. J. Cullen Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin. Cancer Res., October 1, 2006; 12(19): 5817 - 5825. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Chanvorachote, U. Nimmannit, C. Stehlik, L. Wang, B.-H. Jiang, B. Ongpipatanakul, and Y. Rojanasakul Nitric Oxide Regulates Cell Sensitivity to Cisplatin-Induced Apoptosis through S-Nitrosylation and Inhibition of Bcl-2 Ubiquitination. Cancer Res., June 15, 2006; 66(12): 6353 - 6360. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-C. Yen and W. W. Lamph The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma Mol. Cancer Ther., May 1, 2005; 4(5): 824 - 834. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Meurette, L. Lefeuvre-Orfila, A. Rebillard, D. Lagadic-Gossmann, and M.-T. Dimanche-Boitrel Role of Intracellular Glutathione in Cell Sensitivity to the Apoptosis Induced by Tumor Necrosis Factor {alpha}-Related Apoptosis-Inducing Ligand/Anticancer Drug Combinations Clin. Cancer Res., April 15, 2005; 11(8): 3075 - 3083. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Anderson, K. A. Lawson, M. Simmons-Menchaca, L. Sun, B. G. Sanders, and K. Kline {alpha}-TEA Plus Cisplatin Reduces Human Cisplatin-Resistant Ovarian Cancer Cell Tumor Burden and Metastasis Experimental Biology and Medicine, December 1, 2004; 229(11): 1169 - 1176. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Panduri, S. A. Weitzman, N. S. Chandel, and D. W. Kamp Mitochondrial-derived free radicals mediate asbestos-induced alveolar epithelial cell apoptosis Am J Physiol Lung Cell Mol Physiol, June 1, 2004; 286(6): L1220 - L1227. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ortega, P. Ferrer, J. Carretero, E. Obrador, M. Asensi, J. A. Pellicer, and J. M. Estrela Down-regulation of Glutathione and Bcl-2 Synthesis in Mouse B16 Melanoma Cells Avoids Their Survival during Interaction with the Vascular Endothelium J. Biol. Chem., October 10, 2003; 278(41): 39591 - 39599. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |